Kejal Kantarci
Professor of Radiology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Objective Lewy body disease (LBD) is a complex neurodegenerative disorder characterized by the accumulation of misfolded α‐synuclein in the brain. Neuroinflammation has long been implicated in LBD pathogenesis, and recent genetic studies in Parkinson's disease (a clinical manifestation of LBD) have shown consistent association with the human leukocyte antigen (HLA) gene complex. Here, we assessed whether variation in HLA alleles influences neuropathological burden in a neuropathologically‐defined series of LBD cases. Methods We conducted a comprehensive analysis of HLA allelic variants in a cohort of 539 LBD cases of European descent from the Mayo Clinic brain bank. High‐resolution whole‐genome sequencing was used, and the HLA alleles of each sample were called using the HLA*LA tool and assessed for association with neuropathological outcomes. Results Our analysis identified 1 significant ( P < 3.43 × 10 −5 ) and 4 suggestive ( P < 0.001) associations between certain HLA alleles and specific neuropathological outcomes in LBD, suggesting a potential role for HLA‐mediated immune mechanisms in disease progression and subtype differentiation. Specifically, HLA‐DPB1*06:01 was significantly associated with lower Lewy body counts in the parahippocampal gyrus ( P = 3.30 × 10 −5 ), with weaker and suggestive associations observed in the middle frontal ( P = 1.80 × 10 −4 ) and inferior parietal gyrus ( P = 6.33 × 10 −4 ). Additionally, although only suggestive, HLA‐DRB1*11:01 correlated with a lower Thal amyloid phase ( P = 1.56 x 10 −4 ), and HLA‐B*15:01 correlated with an increased risk of diffuse LBD ( P = 7.58 x 10 −4 ). Interpretation This study provides a detailed evaluation of the relationship between HLA alleles and LBD pathology, highlighting the importance of immune‐related genetic factors in the etiology of LBD. ANN NEUROL 2026;99:492–501
Year:
2026
Background Converging evidence hints at neurodevelopmental effects in people at risk of genetic frontotemporal dementia (FTD). Objective We investigated total intracranial volume (TIV), a neuroimaging marker of neurodevelopment, and years of education differences between adult mutation carriers and familial non-mutation carriers, as measures of the structural and functional neurodevelopmental effects of FTD-causing genetic mutations. Methods This cross-sectional cohort study, facilitated through the FTD Prevention Initiative (FPI), included 902 adult pathogenic mutation carriers of GRN , MAPT , or C9orf72 , and 532 familial non-carriers. ANCOVAs were computed to compare TIV and education between groups per gene. Pearson's correlations were used to examine associations between TIV and education. Results Mutation carriers (mean ± SD age = 50.0 ± 13.2 years, sex = 55% female, n ( GRN ) = 298, n( MAPT ) = 187, n ( C9orf72 ) = 417) were compared to familial non-carriers (age = 48.0 ± 12.9 years, sex = 58% female, n ( GRN ) = 201, n( MAPT ) = 114), n ( C9orf72 ) = 217). Consistent with prior findings in young adults, GRN carriers showed larger TIV, on average by 20531 mm 3 , compared to familial non-carriers (95% CI [85.4, 40977], p = 0.049, η 2 p = 0.008). Larger TIV correlated with higher years of education in GRN carriers (95% CI [0.01, 0.24], r (295) = 0.12, p = 0.03) and GRN non-carriers (95% CI [0.08, 0.34], r(198) = 0.21, p = 0.002). MAPT carriers demonstrated smaller TIV than non-carriers, on average by 29896 mm 3 (95% CI [–58248, −1545], p = 0.039, η 2 p = 0.02). Models with C9orf72 and education as outcome variables did not reveal significant differences. Conclusions In support of the neurodevelopmental hypothesis of FTD, GRN and MAPT mutations are linked to structural neurodevelopmental changes in TIV. Further research is needed to identify mechanisms underlying neurodevelopmental influences of FTD mutations and ascertain their suitability as intervention targets.
Year:
2026
Year:
2026
The study assesses the relationship between thalamic proton-MR spectroscopy (1H-MRS) metabolites and thalamic 11C-ER176 translocator-protein positron emission tomography (TSPO-PET) standardized uptake value ratios (SUVR) to advance our understanding of thalamic involvement in multiple sclerosis (MS)-associated neurodegeneration and disability. In this prospective cross-sectional study, patients with MS (pwMS) and controls underwent 3T-MRI, 1H-MRS, and 11C-ER176-PET targeting the thalamus. MRI-derived thalamic volume was normalized by intracranial volume. 1H-MRS metabolites—N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln), total choline (tCho), and myo-inositol (mIns)—were normalized to total creatine (tCr). Clinical disability was evaluated using MS-specific tests of Expanded Disability Status Scale-EDSS and MS-functional composite-MSFC (including Paced Auditory Serial Addition Test-PASAT). Compared to controls (n = 30), pwMS (n = 21) exhibited smaller thalamic volume, higher thalamic 1H-MRS mIns/tCr (putative gliosis marker), and higher thalamic 11C-ER176-PET SUVR (glial density marker). In pwMS, higher thalamic mIns/tCr (r = −0.67) and tCho/tCr (r = −0.52) correlated with smaller thalamic volume. In pwMS, higher thalamic mIns/tCr correlated with higher thalamic 11C-ER176-PET SUVR (r = 0.48) and decreased cognitive function (PASAT, rho = −0.48). In controls, decreased thalamic NAA/tCr correlated with increased thalamic 11C-ER176-PET SUVR (r = −0.41). Thalamus, a core central nervous system relay, is affected early in MS disease course. Glial-mediated innate immune activation in the thalamus, evaluated by increased 1H-MRS mIns/tCr and 11C-ER176-PET SUVR, is associated with loss of thalamic volume and increased disability in pwMS. The multimodal imaging approach with 1H-MRS mIns/tCr and 11C-ER176-PET SUVR emerges as potential glial biomarkers, to better understand disease mechanisms and evaluate therapeutic interventions targeting glial activity in MS.
Year:
2025
Year:
2025
INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.
Year:
2025
Neurodegenerative diseases like Alzheimer’s are difficult to diagnose due to brain complexity and imaging variability. However, volumetric analysis tools, using reference curves, help detect abnormal brain atrophy and support diagnosis and monitoring. This study evaluates the robustness of three segmentation algorithms, AssemblyNet, FastSurfer and FreeSurfer, in constructing brain volume reference curves and detecting hippocampal atrophy. Using data from 3,730 cognitively normal subjects, we built reference curves and assessed robustness to magnetic field strength (1.5T vs. 3T) using four error metrics (sMAPE, sMSPE, wMAPE, sMdAPE) with bootstrap validation. We evaluated classification performance using hippocampal atrophy rates and HAVAs scores (Hippocampal-Amygdalo-Ventricular Atrophy scores). AssemblyNet shows the lowest errors across all robustness metrics. In contrast, FastSurfer and FreeSurfer exhibit greater deviations, indicating higher sensitivity to field strength variability. AssemblyNet provides consistent hippocampal atrophy rates across all reference models, despite slightly lower sensitivity, while FastSurfer and FreeSurfer display greater variability. Specificity ranges from 0.87 to 0.91 for AssemblyNet, compared to 0.76-0.93 for FastSurfer and 0.86-0.93 for FreeSurfer. Using the HAVAs score, all methods detect high atrophy rates in Alzheimer’s patients. FastSurfer achieves the highest sensitivity (0.98), while AssemblyNet reaches the best specificity (0.95) and the highest balanced accuracy (0.91). This study underscores the importance of algorithm choice for reliable brain volumetric analysis in heterogeneous imaging environments. Among the methods tested, AssemblyNet stands out as both sensitive to Alzheimer’s-related atrophy and robust to acquisition variability, making it a strong candidate when analyzing hippocampal volumes in large, multi-site datasets.
Year:
2025
Year:
2025
Year:
2025
INTRODUCTION Primary age‐related tauopathy (PART) is defined by neurofibrillary tangles (NFTs) with absent‐minimal amyloid beta (Aβ) plaques. Currently, definitive diagnosis of PART occurs with autopsy. This study investigated whether [ 18 F]fluorodeoxyglucose positron emission tomography (FDG‐PET) could detect PART‐related metabolic changes and assessed the impact of common co‐pathologies. METHODS We performed a retrospective cross‐sectional study of 88 individuals (mean age 85.6) with autopsy‐confirmed PART (Braak I to IV; Thal phases 0 to 2) who underwent ante mortem FDG‐PET. Visual ratings and standardized uptake value ratios (SUVRs) were analyzed in medial and lateral temporal lobes, inferior temporal pole, precuneus, and posterior cingulate regions. RESULTS Medial temporal hypometabolism was observed in PART, in the presence of co‐pathologies. Argyrophilic grain disease and TAR DNA‐binding protein 43 were associated with greater hypometabolism ( p < 0.01). Lewy body disease affected parietal regions. DISCUSSION FDG‐PET reveals that PART‐related hypometabolism occurs when co‐pathologies are present, but PART alone appears to have minimal effect on medial temporal lobe hypometabolism. Highlights FDG‐PET hypometabolism worsens with Braak NFT stage. FDG‐PET detects mild lateral temporal lobe hypometabolism in PART alone. PART alone has a minimal effect on medial temporal lobe hypometabolism. Medial temporal hypometabolism is worse in PART with TDP‐43 and especially AGD. The presence of LBD contributes to parietal hypometabolism on FGD‐PET in PART.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (35)
Christopher Butler
Clinical Reader in Complex and Chronic Diseases
Imperial College London
Arabella Bouzigues
University College London
Prashanthi Vemuri
Professor of Radiology
Mayo Clinic
James Joers
University of Minnesota
Albert Aboseif
Assistant Professor of Neurology
UCLA Health
Lize Jiskoot
Assistant professor
Erasmus University Rotterdam
Sonja Scholz
National Institute of Neurological Disorders and Stroke
Martina Bocchetta
Associate Professor (Teaching) in Neuroscience
Brunel University London
Owen Ross
Associate Professor
Mayo Clinic
Caroline Graff
Professor,MD PhD
Karolinska Institutet
David Knopman
Professor
Mayo Clinic Rochester
Henry Rusinek
Professor
New York University Grossman School of Medicine
Erik K. St Louis
Center for Sleep Medicine
Mayo Clinic College of Medicine and Science
Nabeela Nathoo
Assistant Professor, Neurologist
University of Alberta
Dinesh Deelchand
Faculty, Assistant Professor
University of Minnesota
Marissa Schafer
Associate Professor
Mayo Clinic
Jared Brosch
Associate Professor
Indiana University
Bryan Neth
Senior Associate Consultant (Neurology, Oncology), Assistant Professor of Neurology
Mayo Clinic
Joshua Bornhorst
Professor
Mayo Clinic
Fabienne Fiesel
Assistant Professor
Mayo Clinic
Lubna Pal
Professor
Yale University School of Medicine
Gustavo Jimenez-Maggiora
Assistant Professor of Research Neurology
University of Southern California
Christopher Schwarz
Associate Professor of Radiology
Mayo Clinic Rochester
Nick Corriveau-Lecavalier
Assistant Professor
Mayo Clinic
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
John Port
Professor and Consultant
Mayo Clinic
Neill Graff-Radford
Professor
Mayo Clinic Florida
Shunsuke Koga
Hospital of the University of Pennsylvania
Raymond Turner
Vice Chair, Professor with tenure
Georgetown University
Hoon-Ki Min
Associate Professor
Mayo Clinic Rochester
Melissa Armstrong
University of Florida Health
Hugo Botha
Assistant Professor
Mayo Clinic
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Clifford Jack
Professor of Radiology
-
Gulin Oz
Faculty, Professor
University of Minnesota
Make your next move.
Prepare your application
Review drafts before you send them.